A5090659723- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Gastrointestinal Tumor Research and Treatment
- Metastasis and carcinoma case studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Treatment and Pharmacology
- Esophageal Cancer Research and Treatment
- Lung Cancer Treatments and Mutations
- Helicobacter pylori-related gastroenterology studies
- Esophageal and GI Pathology
- Antibiotics Pharmacokinetics and Efficacy
- Epilepsy research and treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Food Quality and Safety Studies
- Drug-Induced Adverse Reactions
- Colorectal and Anal Carcinomas
- PI3K/AKT/mTOR signaling in cancer
- Gastrointestinal disorders and treatments
- Electrostatic Discharge in Electronics
- Multiple and Secondary Primary Cancers
- Acute Myeloid Leukemia Research
- Metabolism and Genetic Disorders
- Neuroendocrine Tumor Research Advances
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
Kanagawa Cancer Center
2011-2020
Kanagawa Prefectural Hospital Organization
2011-2020
Japan Clinical Cancer Research Organization
2011-2013
Kitasato University
2006-2009
HeidelbergCement (Sweden)
2009
Lam Research (Austria)
2009
Kitasato University Hospital
1999-2006
Kitasato University East Hospital
2004-2006
Nanoparticle albumin-bound (nab)-paclitaxel was developed to improve paclitaxel solubility and does not need premedication avoid infusion-related reactions associated with solvent-based (sb)-paclitaxel. We conducted a phase II trial investigate the efficacy safety of nab-paclitaxel plus ramucirumab combination therapy for previously treated advanced gastric cancer.Patients unresectable cancer refractory first-line chemotherapy were administered 100 mg/m2 intravenously on days 1, 8 15, mg/kg...
Abstract Background In the ABSOLUTE trial, weekly nanoparticle albumin-bound paclitaxel (w-nab-PTX) showed non-inferiority to solvent-based (w-sb-PTX) for overall survival (OS). Thus, w-nab-PTX might be an option second-line chemotherapy in advanced gastric cancer (AGC). However, predictive factors efficacies of these agents have not been evaluated. Methods Patients previously enrolled trial were divided into apparent peritoneal metastasis group (PM group) and no (no PM based on baseline...
Several studies have suggested that chemotherapy prolonged survival in patients with metastatic or recurrent small bowel adenocarcinoma (SBA); however, there is still no standard regimen. Here, we evaluated the efficacy and safety of a 5-fluorouracil (5-FU)/L-leucovorin (l-LV)/oxaliplatin (mFOLFOX6) protocol as first-line therapy for SBA. This was multicenter, single-arm, open-label phase II study. Eligibility criteria included histologically confirmed adenocarcinoma, age 20–80 years, an...
A multicenter trial was conducted to evaluate the efficacy and safety of paclitaxel every 2 weeks in patients with advanced or recurrent gastric cancer who had previously received fluoropyrimidine-based chemotherapy. The subjects were disease progression recurrence while receiving All adequate major organ functions an Eastern Cooperative Oncology Group performance status (PS) 0–2. Paclitaxel 140 mg/m2 administered intravenously on days 1 15 a 4-week cycle. primary endpoint response rate....
A phase III trial of S-1 plus cisplatin (SP) versus alone, for first-line treatment advanced gastric cancer (SPIRITS trial), has shown that overall survival was better in patients treated with SP than alone. In the present retrospective biomarker study, we aimed to develop a methodology identify who would respond alone SP. We studied 120 received or chemotherapy cancer, and quantitatively evaluated mRNA levels thymidylate synthase (TS), thymidine phosphorylase (TP), orotate...
Background: We have been attempting to improve the safety, reliability and simplicity of endoscopic submucosal dissection for treatment early esophageal cancer shorten time needed this operation. Methods: The present study involved nine patients with well‐differentiated intramucosal over 20 mm in diameter. Two‐point fixed was carried out. Results: In all cases, mucosal area be dissected successfully identified kept under direct vision, allowing two‐point fixation mucosa forceps hood during...
Background Alcohol consumption combined with inactive aldehyde dehydrogenase-2 (ALDH2) and the presence of multiple esophageal Lugol-voiding lesions (LVLs; dysplasia) are strong predictors for development squamous cell carcinoma (ESCC) in East Asians. We invented a health risk appraisal (HRA) model predicting ESCC based on drinking, smoking, dietary habits, alcohol flushing, i.e., past or present facial flushing after drinking glass beer, surrogate marker ALDH2. Methods Prospective follow-up...
<i>Objective:</i> This dose-escalation study of a combination docetaxel, cisplatin and S-1 investigated the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), recommended (RD) antitumor activity in advanced gastric cancer. <i>Patients Methods:</i> Patients received docetaxel (40 mg/m<sup>2</sup>), (DIV on day 1) mg/m<sup>2</sup> p.o., twice daily, days 1–14 every 28 days). The starting was 60 (level 1); escalated to 70 2) 80 3)...
This study aimed to determine whether combination S-1 plus cisplatin (CDDP) therapy, the most widely used therapy for Japanese patients with advanced gastric cancer, and novel oral antiangiogenic agent TSU-68 could contribute cancer treatment. Ninety-three chemotherapy-naïve unresectable or recurrent cancers were randomised into two groups: S-1/CDDP (group A) B) groups. Both patient groups received identical CDDP dosages. was orally administered 35 consecutive days. Group B twice daily three...
ObjectiveOral fluoropyrimidine plus cisplatin is a standard treatment for advanced gastric cancer, but patients with severe peritoneal metastasis often cannot tolerate this regimen. The aim of study was to assess the feasibility fluorouracil, l-leucovorin and paclitaxel therapy in such patients.
Abstract Background. Capecitabine is used mainly with oxaliplatin to treat metastatic colorectal cancer (mCRC). Results from capecitabine plus irinotecan (XELIRI) or without bevacizumab (BV) have been reported in Europe but not Japan. Consequently, the safety and efficacy of XELIRI BV Japanese patients mCRC were assessed a single-arm phase II study. Methods. Eligible had prior chemotherapy containing for wild-type heterozygous UGT1A1. Therapy each 21-day treatment cycle consisted (800 mg/m2...
4009 Background: Doublet chemotherapy with S-1 and cisplatin (CS) is one of the standard first-line for advanced gastric cancer in Japan. Triplet docetaxel added to CS (DCS) showed a promising activity associated feasible toxicities phase II study. We conducted III study, JCOG1013, investigate whether DCS improved overall survival (OS) compared CS. Methods: Patients previously untreated, human epidermal growth factor receptor 2 negative or unknown, unresectable recurrent adenocarcinoma,...
As the World Health Organization grading system for gastroenteropancreatic-neuroendocrine tumors (GEP-NETs) may not always correlate with tumor progression, it is imperative that other independent predictors of progression be established. To identify such predictors, we conducted a retrospective histopathological study hindgut NETs, obtained from endoscopic procedures, and used statistical analyses to evaluate predictive factors.We first clinicopathological data cases NETs. Tissue sections...
We describe a case of small-cell carcinoma the esophagus associated with paraneoplastic neurological syndrome. Sensorimotor neuropathy had developed 3 years earlier, and symptoms slowly worsened. Small-cell was incidentally diagnosed while investigating cause symptoms. A syndrome on basis cancer exclusion other known causes The patient given combination chemoradiotherapy. There complete response to three courses chemoradiotherapy, no evidence disease recurrence 6 after diagnosis. progression...
<i>Background:</i> Serotonin receptor antagonists are recommended by the American Society of Clinical Oncology for prevention acute and delayed chemotherapy-induced emesis. However, most effective agent in this class antiemetic drugs preventing emesis has not been clearly defined. We therefore performed a double-blind, crossover, randomized, controlled trial comparing efficacy granisetron ramosetron, using patient preference as primary endpoint. <i>Methods:</i> Thirty...
High thymidine kinase 1 (TK1) activity increases the incorporation of trifluridine (FTD) into DNA; thus, FTD antitumor is likely to increase in patients with high tumoral TK1 activity. To date, no established predictive biomarker indicate clinical benefit FTD/tipiracil (TPI) has been identified. We aimed determine relationship between expression and FTD/TPI efficacy refractory metastatic colorectal cancer.Individual patient data from 2 randomized placebo-controlled trials were analyzed....
Objectives: Since the development of techniques for endoscopic submucosal dissection (ESD), indication range resection (ER) has been extended in early gastric cancer (EGC) treatment. For undifferentiated-type EGC, tumors with an intramucosal depth invasion, no ulceration and a diameter 20 mm or less were included expanded indications ER Japanese Gastric Cancer Treatment Guidelines 2010. Nonetheless, because difficulty detecting lesions that meet criteria ER, number endoscopically resected...